Q-omics provides the consensus-scored RFK profile across patient tissues and cancer cell-line models. RFK expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RFK is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, RFK RNA expression shows 19,222 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LIHC, and UVM as cancer lineages where RFK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFK survival associations across molecular data types. RFK RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFK RNA expression–survival associations across cancer types. High RFK expression shows unfavorable associations in ACC, BLCA, LIHC, LUAD and UCS, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for RFK RNA expression.
This table summarizes RFK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 11. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RFK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFK shows lower tumor expression in COAD and higher tumor expression in LIHC, BRCA, LUAD, STAD and ESCA. The LIHC box plot shows higher RFK RNA expression in tumor versus normal tissue (log2 FC = +0.568, t-test p < 0.001).
This table shows molecular features associated with RFK in patient tissues and cancer cell lines. In patient samples, RFK shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RFK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
